|
64 Companies |
|
21 Products |
|
21 Products |
|
23 Mechanisms of Action |
|
207 Trials |
|
10745 News |
|
| «12...125126127128129130131132133134135136137 |
- |||||||||| Soliris (eculizumab) / AstraZeneca
New P3 trial: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (clinicaltrials.gov) - Nov 26, 2013
P3, N=92, Recruiting, Sponsor: Alexion Pharmaceuticals
- prednisone / Generic mfg.
Enrollment change: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Nov 6, 2013
P3, N=11, Terminated, Sponsor: Michael Benatar
N=88 --> 11
- prednisone / Generic mfg.
Trial termination: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Oct 30, 2013
P3, N=11, Terminated, Sponsor: Michael Benatar
N=88 --> 11 Active, not recruiting --> Terminated; Slow recruitment rate
- Clinical: Therapeutic Plasma Exchange in MG (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=10, Recruiting, Sponsor: Duke University
- Enrollment change: CoRDS: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=10000, Recruiting, Sponsor: Sanford Health
Active, not recruiting --> Terminated; Slow recruitment rate N=1000 --> 10000
- | Benlysta (belimumab) / GSK
Enrollment open: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - May 8, 2013
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
N=1000 --> 10000 Not yet recruiting --> Recruiting
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Clinical: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=10, Recruiting, Sponsor: St. Louis University
- New P3 trial: Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome (clinicaltrials.gov) - Apr 3, 2013
P3, N=0, Available, Sponsor: University of Colorado, Denver
- Clinical: CoRDS: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=10000, Recruiting, Sponsor: Sanford Health
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: A Pilot Trial of Rituxan in Refractory Myasthenia Gravis (clinicaltrials.gov) - Jan 14, 2013
P1/2, N=10, Completed, Sponsor: University of Vermont
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: FORCE: Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis (clinicaltrials.gov) - Dec 9, 2012
P2, N=30, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Recruiting --> Completed
- | prednisone / Generic mfg.
Enrollment closed: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (clinicaltrials.gov) - Dec 3, 2012
P3, N=150, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Efficacy of Methotrexate in Myasthenia Gravis (clinicaltrials.gov) - Nov 20, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Kansas
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || leflunomide / Generic mfg., azathioprine / Generic mfg.
New P3 trial: The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy (clinicaltrials.gov) - Nov 13, 2012
P3, N=158, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
- tirasemtiv (CK-2017357) / Astellas, Cytokinetics
Trial termination: Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Oct 29, 2012
P2, N=32, Terminated, Sponsor: Cytokinetics
Recruiting --> Active, not recruiting Recruiting --> Terminated; Closed after complete treatment of 32 patients after 21 months' recruitment.
- | Benlysta (belimumab) / GSK
Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Sep 12, 2012
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Terminated; Closed after complete treatment of 32 patients after 21 months' recruitment. N=120 --> 42
- Enrollment change: Training for Diagnosing Neurological Disorders (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=400, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=120 --> 42 N=200 --> 400
- | New P2 trial: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jan 17, 2012
P2, N=30, Recruiting, Sponsor: Jacobus Pharmaceutical
- prednisone / Generic mfg.
Trial initiation date: EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) - Dec 28, 2011
P3, N=11, Terminated, Sponsor: Michael Benatar
N=200 --> 400 Initiation date: May 2011 --> Dec 2011
- Enrollment closed: The Role of the Thymus in Myasthenia Gravis (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=80, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Initiation date: May 2011 --> Dec 2011 Recruiting --> Active, not recruiting
- | Benlysta (belimumab) / GSK
New P2 trial: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Nov 27, 2011
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
- | Soliris (eculizumab) / AstraZeneca
Enrollment change: Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 16, 2011
P2, N=14, Completed, Sponsor: Alexion Pharmaceuticals
Recruiting --> Active, not recruiting N=24 --> 14
- | Soliris (eculizumab) / AstraZeneca
Trial completion: Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - Nov 16, 2011
P2, N=14, Completed, Sponsor: Alexion Pharmaceuticals
N=24 --> 14 Active, not recruiting --> Completed
- Clinical: Perception and Multisensory Integration in Neurological Patients Using fMRI (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=30, Not yet recruiting, Sponsor: Hadassah Medical Organization
- | prednisone / Generic mfg.
Enrollment change: Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (clinicaltrials.gov) - Oct 18, 2011
P3, N=150, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed N=200 --> 150
- Benlysta (belimumab) / GSK
New P2 trial, IO biomarker: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG) (EUDRACT) - Oct 4, 2011
P2, N=6, Ongoing, Sponsor: GlaxoSmithKline Research & Development Limited